Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Published byMerilyn Underwood Modified over 8 years ago

Similar presentations

Presentation on theme: "Baseline characteristics of HPS participants by prior cerebrovascular disease."— Presentation transcript:

1

2 Baseline characteristics of HPS participants by prior cerebrovascular disease

3 Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior cerebrovascular disease

4 Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior cerebrovascular disease

5 FACTORIAL TREATMENT COMPARISONS

6 (10269)(10267) SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Type 290409 Ischaemic 5153 Haemorrhagic 103134 Unknown Severity 96119 Fatal 4251 Severe 107155 Moderate 138189 Mild 6171 Unknown (4.3%)(5.7%) 25% SE 5 reduction 444585 (2P<0.00001) ALL STROKES 0.40.60.81.01.21.4 HPS: Stroke Incidence

7 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Age (years) < 65164195(3.3%)(4.0%) ≥ 65 < 70110154(4.5%)(6.3%) ≥ 70170236(5.8%)(8.2%) Sex Male331453(4.3%)(5.9%) Female113132(4.4%)(5.2%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: STROKE incidence by AGE & SEX

8 (10269)(10267) SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature Age 8311091(16.9%)(22.1%)< 65 512665(20.9%)(27.2%)65 - 69 548620(23.8%)(27.7%)70 - 74 142209(23.1%)(32.3%)  75 Sex 16662135(21.6%)(27.6%)Male 367450(14.4%)(17.7%)Female 24% SE 3 reduction (2P<0.00001) 20332585(19.8%)(25.2%)ALL PATIENTS 0.40.60.81.01.21.4 HPS: MAJOR VASCULAR EVENT by AGE & SEX

9 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Prior coronary disease Yes265347(4.0%)(5.2%) No179238(5.0%)(6.7%) Prior cerebrovascular disease Yes169170(10.3%)(10.4%) No275415(3.2%)(4.8%) Prior diabetes Yes149193(5.0%)(6.5%) No295392(4.0%)(5.4%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: STROKE by PRIOR DISEASE

10 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Prior coronary disease Yes175237(2.6%)(3.5%) No115172(3.2%)(4.8%) Prior cerebrovascular disease Yes100122(6.1%)(7.5%) No190287(2.2%)(3.3%) Prior diabetes Yes102140(3.4%)(4.7%) No188269(2.6%)(3.7%) ALL PATIENTS290409(2.8%)(4.0%) 30% SE 6 reduction (2P<0.00001wœ4õ) 0.40.60.81.01.21.4 HPS: ISCHAEMIC STROKE by PRIOR DISEASE

11 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Prior coronary disease Yes14591841(21.8%)(27.5%) No574744(16.1%)(20.8%) Prior cerebrovascular disease Yes406488(24.7%)(29.8%) No16272097(18.9%)(24.3%) Prior diabetes Yes601748(20.2%)(25.1%) No14321837(19.6%)(25.2%) ALL PATIENTS20332585(19.8%)(25.2%) 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: MAJOR VASCULAR EVENTS by PRIOR DISEASE

12 Absolute effects on major vascular events and strokes subdivided by prior cerebrovascular disease S S P P Yes No Prior cerebrovascular disease Major vascular event (%) Risk reductions (SE): Proportional Absolute/1000 P-value 20% (6) 58 (18) p=0.001 25% (3) 60 (7) p<0.0001 Other event Stroke

13 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) LDL cholesterol (mmol/L) < 3.0137194(4.0%)(5.7%) ≥ 3.0 < 3.5108155(4.2%)(6.2%) > 3.5199236(4.6%)(5.4%) HDL cholesterol (mmol/L) < 0.9170199(4.7%)(5.6%) ≥ 0.9 < 1.1115166(4.1%)(5.8%) > 1.1159220(4.1%)(5.7%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: STROKE incidence by BASELINE LIPIDS

14 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) LDL cholesterol (mmol/L) < 3.0598756(17.6%)(22.2%) ≥ 3.0 < 3.5484646(19.0%)(25.7%) > 3.59511183(22.0%)(27.2%) HDL cholesterol (mmol/L) < 0.98181064(22.6%)(29.9%) ≥ 0.9 < 1.1560720(20.0%)(25.1%) > 1.1655801(17.0%)(20.9%) ALL PATIENTS20332585(19.8%)(25.2%) 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: MAJOR VASCULAR EVENTS by BASELINE LIPIDS

15 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Diastolic blood pressure (mmHg) < 80176239(3.9%)(5.2%) ≥ 80 < 90131185(4.0%)(5.8%) ≥ 90137160(5.6%)(6.5%) Systolic blood pressure (mmHg) < 140162189(3.6%)(4.2%) ≥ 140 < 160121169(3.9%)(5.3%) ≥ 160161226(6.1%)(8.8%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: STROKE incidence by baseline BLOOD PRESSURE

16 (10269)(10267) SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature DBP (mmHg) 9171210(20.4%)(26.4%)< 80 644753(19.5%)(23.5%)  80 < 90 472621(19.2%)(25.1%)  90 SBP (mmHg) 8801064(19.4%)(23.5%)< 140 553772(17.9%)(24.4%)  140 < 160 600748(22.7%)(29.2%)  160 24% SE 3 reduction (2P<0.00001) 20332585(19.8%)(25.2%)ALL PATIENTS 0.40.60.81.01.21.4 HPS: MAJOR VASCULAR EVENTS by baseline BLOOD PRESSURE

17 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Treated hypertension Yes223274(5.3%)(6.5%) No221311(3.6%)(5.2%) Aspirin Yes286378(4.4%)(5.8%) No158207(4.2%)(5.5%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: STROKE incidence by TREATED HYPERTENSION and ASPIRIN USE

18 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Treated hypertension Yes9421195(22.4%)(28.1%) No10911390(18.0%)(23.1%) Aspirin Yes13701784(21.1%)(27.4%) No663801(17.5%)(21.3%) ALL PATIENTS20332585(19.8%)(25.2%) 24% SE 3 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS: MAJOR VASCULAR EVENTS by TREATED HYPERTENSION & ASPIRIN USE

19 SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Year of follow-up (10269)(10267) 187106(0.8%)(1.0%) 281132(0.8%)(1.3%) 382111(0.8%)(1.2%) 481111(0.9%)(1.2%) 5+113125(1.2%)(1.4%) ALL PATIENTS444585(4.3%)(5.7%) 25% SE 5 reduction (2P<0.00001) 0.40.60.81.01.21.4 HPS : STROKE incidence by YEAR

20 Years of follow-up PLACEBO SIMVASTATIN Benefit/1000(SE)2(1)7(2)10(2)13(3)14(4)15(10) Logrank p<0.0001 0123456 0 1 2 3 4 5 6 7 Proportion with stroke HPS: STROKE by YEAR

21 STATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Study GREACE917(1.1%)(2.1%) AFCAPS/TexcAPS1417(0.4%)(0.5%) Post-CABG1816(2.7%)(2.4%) GISSI2019(0.9%) WOSCOPS4651(1.4%)(1.5%) CARE5276(2.5%)(3.7%) SSSS5676(2.5%)(3.4%) ASCOT89121(1.7%)(2.4%) PROSPER135131(4.7%)(4.5%) LIPID169204(3.7%)(4.5%) ALLHAT209231(4.0%)(4.5%) HPS444585(4.3%)(5.7%) ALL PATIENTS12611544(3.0%)(3.6%) 21% SE 4 reduction (2P<0.00001) 0.40.60.81.01.21.4 Effects on STROKE in major STATIN trials

22 HPS: Conclusions for people with cerebrovascular disease Lowering LDL cholesterol by 1 mmol/L (40 mg/dL) reduces the 5-year risk of ischaemic stroke by about one-quarter, with no apparent adverse effect on cerebral haemorrhage Similar proportional reductions in stroke risk are seen with statin therapy irrespective of age, sex, lipid levels, blood pressure, or use of other medications (including aspirin) Statin therapy clearly reduces the risk of major vascular events among people with pre-existing cerebrovascular disease, irrespective of the presence of coronary disease

Download ppt "Baseline characteristics of HPS participants by prior cerebrovascular disease."

Similar presentations

Funding to Oxford University for MRC/BHF Heart Protection Study Medical Research Council$14M British Heart Foundation$2M Merck $8M Roche Vitamins$8M Designed,

Funding to Oxford University for MRC/BHF Heart Protection Study Medical Research Council$14M British Heart Foundation$2M Merck $8M Roche Vitamins$8M Designed,
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.

CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9:269-279. LaRosa JC et al. N Engl J Med. 2005;352:1425-1435.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
IHS SDPI COMPETITIVE GRANT PROGRAM CVD RISK REDUCTION DEMONSTRATION PROJECT WHAT IS THE EVIDENCE? HOW ARE WE DOING? HOW CAN WE DO BETTER? Karl Hammermeister,

IHS SDPI COMPETITIVE GRANT PROGRAM CVD RISK REDUCTION DEMONSTRATION PROJECT WHAT IS THE EVIDENCE? HOW ARE WE DOING? HOW CAN WE DO BETTER? Karl Hammermeister,
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Lancet 2005 366: 1267-1134 doi:10.1016/S0140-6736(08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol 5.5-8.0 Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Who should have statins 18 th March 2013. 0.40.60.811.21.4 Nonfatal MI CHD death Any major coronary event CABG PTCA Unspecified Any coronary revascularisation.

Who should have statins 18 th March Nonfatal MI CHD death Any major coronary event CABG PTCA Unspecified Any coronary revascularisation.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Rationale, Study Design & Study Population

Rationale, Study Design & Study Population
Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.

ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Similar presentations

Ads by Google